ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,036.77
      0.70%
      US Tech 100
      20,980.80
      1.24%
      Dow Jones
      44,575.06
      0.34%
      Brent Oil
      76.175
      1.08%
      Bitcoin
      99,335.60
      -2.07%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Sutro Biopharma Inc (STRO) Quote

      Sutro Biopharma Inc

      Sutro Biopharma Inc (STRO)

      NASDAQ
      1.96
      0.06
      ( 3.16% )
      Updated: 14:29:07
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      1.96
      Bid
      1.96
      Ask
      1.97
      Volume
      876,428
      1.885 Day's Range 1.98
      1.67 52 Week Range 6.13
      Market Cap
      161.619M
      Previous Close
      1.90
      Open
      1.91
      Last Trade
      3
      @
      1.965
      Last Trade Time
      14:36:13
      Financial Volume
      $ 1,702,327
      VWAP
      1.9423
      Average Volume (3m)
      1,087,567
      Shares Outstanding
      82,458,725
      Dividend Yield
      -
      PE Ratio
      -1.52
      Earnings Per Share (EPS)
      -1.3
      Revenue
      153.73M
      Net Profit
      -106.79M

      About Sutro Biopharma Inc

      Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated ce... Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.sutrobio.com
      Headquarters
      South San Francisco, California, USA
      Founded
      -
      Sutro Biopharma Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker STRO. The last closing price for Sutro Biopharma was $1.90. Over the last year, Sutro Biopharma shares have traded in a share price range of $ 1.67 to $ 6.13.

      Sutro Biopharma currently has 82,458,725 shares outstanding. The market capitalization of Sutro Biopharma is $156.67 million. Sutro Biopharma has a price to earnings ratio (PE ratio) of -1.52.

      Ask ADVFN Intelligence (AI)

      STRO Latest News

      More News

      Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference 

      SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...

      January 07 2025
      GlobeNewswire Inc.

      Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

      SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary...

      January 07 2025
      GlobeNewswire Inc.

      Form 8-K - Current report

      December 10 2024
      Edgar (US Regulatory)

      Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

      - 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial - - These...

      December 10 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      December 03 2024
      Edgar (US Regulatory)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 14 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 13 2024
      Edgar (US Regulatory)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 13 2024
      Edgar (US Regulatory)

      Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

      - Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology - - Two new clinical trials, REFRαME-P1, a registration-enabling...

      November 13 2024
      GlobeNewswire Inc.

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 12 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.02-1.01010101011.982.011.818787521.91022056CS
      4-0.13-6.220095693782.092.151.678384251.9150857CS
      12-2.44-55.45454545454.44.41.6710875672.28095261CS
      26-1.3-39.87730061353.265.171.678153212.95099578CS
      52-2.49-55.95505617984.456.131.678462883.60085167CS
      156-7.68-79.66804979259.6410.151.676695094.6005517CS
      260-10.15-83.815028901712.1128.31.675374017.92036626CS

      STRO - Frequently Asked Questions (FAQ)

      What is the current Sutro Biopharma share price?
      The current share price of Sutro Biopharma is $ 1.96
      How many Sutro Biopharma shares are in issue?
      Sutro Biopharma has 82,458,725 shares in issue
      What is the market cap of Sutro Biopharma?
      The market capitalisation of Sutro Biopharma is USD 156.67M
      What is the 1 year trading range for Sutro Biopharma share price?
      Sutro Biopharma has traded in the range of $ 1.67 to $ 6.13 during the past year
      What is the PE ratio of Sutro Biopharma?
      The price to earnings ratio of Sutro Biopharma is -1.52
      What is the cash to sales ratio of Sutro Biopharma?
      The cash to sales ratio of Sutro Biopharma is 1.06
      What is the reporting currency for Sutro Biopharma?
      Sutro Biopharma reports financial results in USD
      What is the latest annual turnover for Sutro Biopharma?
      The latest annual turnover of Sutro Biopharma is USD 153.73M
      What is the latest annual profit for Sutro Biopharma?
      The latest annual profit of Sutro Biopharma is USD -106.79M
      What is the registered address of Sutro Biopharma?
      The registered address for Sutro Biopharma is 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO, CALIFORNIA, 94080
      What is the Sutro Biopharma website address?
      The website address for Sutro Biopharma is www.sutrobio.com
      Which industry sector does Sutro Biopharma operate in?
      Sutro Biopharma operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CAPTCaptiVision Inc
      $ 1.1393
      (159.52%)
      		220.66M
      QNTMQuantum Biopharma Ltd
      $ 6.22
      (95.60%)
      		60.03M
      LTRYLottery com Inc
      $ 0.5323
      (70.61%)
      		111.84M
      PTIRGraniteShares 2X Long PLTR Daily ETF
      $ 224.26
      (44.39%)
      		1.57M
      PLTUDirexion DAily PLTR Bull 2X Shares
      $ 47.48
      (43.92%)
      		2.37M
      OMGAOmega Therapeutics Inc
      $ 0.155
      (-67.65%)
      		7.69M
      VIRXViracta Therapeutics Inc
      $ 0.0416
      (-46.53%)
      		4.72M
      CYNCYNGN Inc
      $ 0.0755
      (-35.41%)
      		82.63M
      UPCUniverse Pharmaceuticals Inc
      $ 0.2777
      (-33.47%)
      		1.49M
      CSAICloudastructure Inc
      $ 13.35
      (-29.74%)
      		37.45k
      CAPTCaptiVision Inc
      $ 1.1393
      (159.52%)
      		220.64M
      PLTRPalantir Technologies Inc
      $ 102.59
      (22.51%)
      		177.15M
      NVDANVIDIA Corporation
      $ 119.375
      (2.33%)
      		170.71M
      RGTIRigetti Computing Inc
      $ 13.5699
      (0.74%)
      		132.75M
      LTRYLottery com Inc
      $ 0.5323
      (70.61%)
      		111.84M

      STRO Discussion

      View Posts
      Invest-in-America Invest-in-America 1 month ago
      STRO: I launched this new iHub board today due to the below-pasted reply I got from GOOGLE's (AI) search routine regarding my following question: "Which (under $5.00) NASDAQ stock is the most likely to SOAR hugely in price on 1-2-25?"

      "According to current market analysis, Sutro Biopharma Inc. (STRO), a clinical-stage biopharmaceutical company currently trading under $5, is considered a potential candidate for a significant price jump due to its promising cancer treatment pipeline, particularly its lead drug candidate "luveltamab tazevibulin" currently in mid-phase trials, which could lead to substantial investor interest if clinical trials prove successful; however, investing in any penny stock carries high risk and should be done with thorough research and consideration of potential downsides."

      /////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
      And "TipRanks" gives STRO a "Strong Buy" rating, for what that's worth. (But its Float is 76-Million, which ain't small.)
      👍️0

      Your Recent History

      NASDAQ
      STRO
      Sutro Biopharma
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads